http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108187029-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_217f2be73fd6be0be36dd55803d3bec5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2be1db5fe1dc100967a3c2d860335e7 |
| publicationDate | 2018-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108187029-A |
| titleOfInvention | Leukocytic immunity globulin sample receptor subfamily B member 4 is in the application for preparing prevention, alleviating and/or treat myocardial hypertrophy drug |
| abstract | The invention discloses leukocytic immunity globulin sample receptor subfamily B member 4 in the application for preparing prevention, alleviating and/or treat myocardial hypertrophy drug.Select heartspecific Cre mouse and heartspecific LILRB4 knock out mice, operation group gives aorta arch constriction operation, the measure of plump cardiac myocytes, fibrosis and heart function is carried out to each group mouse, shows that the LILRB4 defects caused by knocking out LILRB4 genes significantly deteriorate myocardial hypertrophy, fibrosis and heart function.SD suckling mouse primary cardiomyocytes are infected by recombination adenovirus construction AdshLILRB4 and AdLILRB4, give Ang II stimulation structure cardiac myocyte hypertrophy models, LILRB4 is overexpressed virus and significantly inhibits cardiac myocyte hypertrophy, and myocardial cell surface product reduces, and the result of LILRB4 viral interferences is then opposite.LILRB4, which has, inhibits myocardial hypertrophy and its fibrosis, improves the effect of heart function. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110331164-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110317831-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110331164-A |
| priorityDate | 2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.